Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 9Leukemia 7Leukemia, Myeloid, Acute 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Gliosarcoma 5Glioblastoma 5Brain Neoplasms 5Glioma 4Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Philadelphia Chromosome 3Pancreatic Neoplasms 3Oligodendroglioma 3Myeloproliferative Disorders 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Astrocytoma 3Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Cisplatin 14Pemetrexed 11pembrolizumab 6Cyclophosphamide 6Radiotherapy 3Interleukin-2 3Gemcitabine 3sodium thiosulfate 2sargramostim 2defactinib 2aldesleukin 2Surgical Procedures, Operative 2SS1(dsFv)PE38 2Radiation 2Platinum 2Pharmaceutical Preparations 2Paclitaxel 2Nivolumab 2Drug Therapy 2Depsipeptides 2Decitabine 2Celecoxib 2Carboplatin 21,2-diaminocyclohexaneplatinum II citrate 2osimertinib 1incomplete Freund's adjuvant 1entinostat 1cabozantinib 1bemcentinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mesothelioma, Malignant × Imatinib Mesylate × Clear all
NCT00402766 2015-11-18

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

M.D. Anderson Cancer Center

Phase 1 Completed
19 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡